Mental health disorders more prevalent amongst adults with inflammatory skin conditions
1. Anxiety and depression were more prevalent among individuals with eczema or psoriasis, and those with these inflammatory conditions were ...
Tag: dermatology
2 Minute Medicine Rewind August 7, 2023
Fluctuations in Serum Creatinine Levels During Hospitalization and Long-Term End-Stage Kidney Disease and Mortality 1. Despite returning to a normal ...
Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea
1. In this case series, ruxolitinib was associated with improved inflammatory markers in patients with disabling pansclerotic morphea (DPM). 2. ...
Spironolactone may be effective in the treatment of acne vulgaris
1. Spironolactone showed more effective improvement in acne at 12 and 24 weeks after treatment initiation as compared with the ...
2 Minute Medicine Rewind May 22, 2023
Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers A Phase 3 Randomized Clinical Trial 1. Patients ...
Delay of surgical treatment for melanoma up to 90 days not associated with poorer outcomes
1. In this retrospective cohort study, cutaneous melanomas with a classification of T1b-T4 but without clinical evidence of metastatic disease (N0M0) ...
Dersimelagon reduces symptomatic disease in erythropoietic protoporphyrias
1. In this randomized controlled trial, oral dersimelagon resulted in significantly increased time to first symptoms among patients with erythropoietic ...
Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
1. In two phase three trials, 16 weeks of lebrikizumab treatment effectively treated adolescents and adults with moderate-to-severe atopic dermatitis. ...
#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
